MRK Stock Summary and Trading Ideas (Merck (New) | NYSE:MRK)

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).

Merck (New) trades on the NYSE stock market under the symbol MRK.

As of November 2, 2026, MRK stock price declined to $148.36 with 7,961,512 million shares trading.

MRK has a beta of -0.38, meaning it tends to be less sensitive to market movements. MRK has a correlation of 0.02 to the broad based SPY ETF.

MRK has a market cap of $366.03 billion. This is considered a Mega Cap stock.

Last quarter Merck (New) reported $18 billion in Revenue and $2.49 earnings per share. This beat revenue expectation by $763 million and exceeded earnings estimates by $.39.

In the last 3 years, MRK traded as high as $156.92 and as low as $73.31.

The top ETF exchange traded funds that MRK belongs to (by Net Assets): VTI, VOO, IVV, SCHD, SPY.

MRK has outperformed the market in the last year with a price return of +75.9% while the SPY ETF gained +11.7%. MRK has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +15.0% and +1.7%, respectively, while the SPY returned +1.7% and -1.5%, respectively.

MRK support price is $146.24 and resistance is $152.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRK shares will trade within this expected range on the day.